IP Library Granted Patent US 10,214,580
Granted Patent B2
US 10,214,580 · App. 14/047,301 · Granted Feb 26, 2019

Constructs and libraries comprising antibody surrogate light chain sequences

Inventors: Ramesh Bhatt (Belmont, CA); Lawrence Horowitz (Atherton, CA); Li Xu (Cupertino, CA)
Assignee: I2 PHARMACEUTICALS, INC.
C07K16/00C07K16/005C07K16/1018C07K16/18C07K16/22C07K16/241C40B40/10C07K2317/34C07K2317/52C07K2317/56C07K2317/622C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,214,580
App. No.
14/047,301
Granted
Feb 26, 2019
Kind
B2
Abstract

The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.

Claims (8)

1. A tetrameric construct comprising:

(a) a first and a second surrogate light chain fusion polypeptide, each comprising the amino acid sequence of SEQ ID NO: 10, and;

(b) a first and a second antibody heavy chain polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a heavy chain first constant region (CH1), a hinge region, a heavy chain second constant region (CH2), and a heavy chain third constant region (CH3), wherein each antibody heavy chain polypeptide comprises the amino acid sequence of SEQ ID NO: 9,

wherein the first surrogate light chain fusion polypeptide is non-covalently conjugated to the first antibody heavy chain polypeptide, wherein the second surrogate light chain fusion polypeptide is non-covalently conjugated to the second antibody heavy chain polypeptide, and wherein the construct is capable of specifically binding to a target, wherein the target is an influenza A virus.

2. A tetrameric construct comprising:

(a) a first and a second surrogate light chain fusion polypeptide, each comprising the amino acid sequence of SEQ ID NO: 10, and;

(b) a first and a second antibody heavy chain polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a heavy chain first constant region (CH1), a hinge region, a heavy chain second constant region (CH2), and a heavy chain third constant region (CH3), wherein each antibody heavy chain polypeptide comprises the amino acid sequence of SEQ ID NO: 14,

wherein the first surrogate light chain fusion polypeptide is non-covalently conjugated to the first antibody heavy chain polypeptide, wherein the second surrogate light chain fusion polypeptide is non-covalently conjugated to the second antibody heavy chain polypeptide, and wherein the construct is capable of specifically binding to a target, wherein the target is an influenza A virus.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: REVOPSIS THERAPEUTICS, INC.
To: REVOPSIS HOLDINGS, LLC
Reel/Frame 072793/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2024
From: BIOASSETS, LLC
To: REVOPSIS THERAPEUTICS, INC.
Reel/Frame 066055/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: I2 PHARMACEUTICALS, INC.
To: BIOASSETS, LLC
Reel/Frame 064003/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: HOROWITZ, LAWRENCE; BHATT, RAMESH; XU, LI
To: SEA LANE BIOTECHNOLOGIES, LLC.
Reel/Frame 041130/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: SEA LANE BIOTECHNOLOGIES, LLC.
To: ALTUS BIOPHARMA INC.
Reel/Frame 041154/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: ALTUS BIOPHARMA INC.
To: I2 PHARMACEUTICALS, INC.
Reel/Frame 041154/0613 →
Continuity (4)
Continuation 13371347 · Feb 10, 2012
Continuation 12056151 · Mar 26, 2008
Provisional Application 60920568 · Mar 27, 2007
Related Publication 20140228544A1 · Aug 14, 2014